Alexis Borisy

Alexis Borisy is a leading biotechnology entrepreneur and investor with more than 25 years of experience building, operating and investing in innovative science-based companies to make a positive difference in the world. Alexis co-founded Foundation Medicine (FMI), served as its first CEO, and then chairman, remaining on the board until the $5B acquisition by Roche. He also co-founded Blueprint Medicines, served as interim CEO, and continues to serve on the board. As a partner at Third Rock Ventures for a decade, Alexis also was a founding investor for Editas and Magenta Therapeutics; a co-founder, former CEO, and Chairman of Relay Therapeutics; founding investor and chairman of Tango Therapeutics; and an investor in REVOLUTION Medicines and Insitro, among others.

Alexis founded his first company, CombinatoRx, when he was in his 20s, served as its CEO and brought the company public on the NASDAQ. He has been personally involved in billions of dollars in financing and business development deals, and has authored numerous scientific papers and patents. Graduate trained in chemistry and chemical biology at Harvard where he was a Howard Hughes predoctoral fellow, Alexis was honored as the Massachusetts Institute of Technology’s Technology Review Innovator of the Year. He was also chosen as the New England Entrepreneur of the Year in Life Sciences and was honored as a presidential scholar. He is currently vice chairman of the Board of Trustees of the Boston Museum of Science, has served on the board of BIO, and currently serves as the chairman of the National Venture Capital Association.

Alexis holds an undergraduate degree in chemistry from the University of Chicago.